



ANALYSIS GROUP

Analysis Group Podium Presentations and Posters

2025 ISPE ANNUAL MEETING | AUGUST 22-26 | WASHINGTON, DC

Analysis Group's health care experts apply skills in epidemiology, biostatistics, clinical research, and regulatory strategy to questions across broad therapeutic areas.

This year, we are pleased to present two podium presentations and four posters at the 2025 ISPE Annual Meeting. Please find the details below.

Please stop by and say hello to our team at Booth #206.

2025 ISPE Annual Meeting Podium Presentations Supported by Analysis Group Research

PODIUM PRESENTATION

Monday, August 25 | 5:00–5:15 p.m. ET | Room 208AB

Development of a Rule-based Definition of Clinically Ready for Discharge Status in Hospitalized Patients with Complicated Urinary Tract Infection Treated with Intravenous Carbapenems

Patients hospitalized with complicated urinary tract infection (cUTI) caused by multidrug-resistant uropathogens often need intravenous (IV) carbapenems, requiring extended inpatient (IP) treatment or outpatient administration. We developed a clinically relevant, rule-based CRFD definition based on data from structured EHR and unstructured clinical notes. Our results suggest that >50% of patients with cUTI remained hospitalized longer than clinically necessary, possibly due to the IV carbapenem treatment, underscoring the unmet need for effective oral antibiotic therapy options.

Presenting Author

[Rose Chang](#), Sc.D., M.S., M.S.P.H., *Vice President*

Associated Experts and Consultants

[Mei Sheng Duh](#), Sc.D., M.P.H., *Managing Principal*

[Rose Chang](#), Sc.D., M.S., M.S.P.H., *Vice President*

Louise Yu, M.S., *Associate*

Emily Reichert, M.S., *Senior Analyst*

Joanne Chukwueke, M.P.H., *Research Professional*

Zheyi Cao, M.S., *Analyst*

External Coauthors

GSK: Jeffrey J. Ellis, Pharm.D., M.S.; Douglas Boettner, Ph.D.; and Lindsey Parker, Pharm.D.

Harvard Medical School, Brigham and Women's Hospital: Serena P. Koenig, M.D., Ph.D.

Harvard Medical School, Mass General Brigham: Yichuan Grace Hsieh, Ph.D., M.S.

Mass General Brigham: Christopher Herrick, M.B.A.

Harvard Medical School, Mass General Brigham, Massachusetts General Hospital: Shawn Murphy, M.D., Ph.D.

Funding for this study was provided by GSK.

PODIUM PRESENTATION

Monday, August 25 | 5:15–5:30 p.m. ET | Room 208AB

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results

Patients with triple-class refractory (TCR) multiple myeloma (MM) experience a significant decline in health-related quality of life (QOL) and poor clinical outcomes. This interim analysis suggests a substantial QOL burden among TCR MM patients at baseline. QOL remained stable across both CART-T and non-CART-T cohorts post-index, with select improvements in disease symptoms. However, patients – particularly those receiving CAR-T – reported notable holistic improvements as early as Month 1 based on PGIC assessment.

Presenting Author

[Priyanka Bobbili](#), Sc.D., M.S., M.S.P.H., Vice President

Associated Experts and Consultants

[Mei Sheng Duh](#), Sc.D., M.P.H., Managing Principal

[Priyanka Bobbili](#), Sc.D., M.S., M.S.P.H., Vice President

[Aolin Wang](#), Ph.D., M.Sc., Manager

Jingyi Chen, M.S., Senior Analyst

Manasi Mohan, M.S., Senior Analyst

External Coauthors

Pfizer: Patrick Hlavacek, M.P.H.; Rickard Sandin, Ph.D.; Joseph C. Cappelleri, M.S., Ph.D., M.P.H.; David Hughes, Pharm.D., M.P.H.; Guido Nador, M.D.; and Marco DiBonaventura, Ph.D.

Mayo Clinic: Charis Charalampous, M.D.; Shaji K. Kumar, M.D.; Ricardo Parrondo, M.D.; Saurabh Chhabra, M.B.B.S.; and Madhu Nagaraj, M.D.

Funding for this study was provided by Pfizer.

2025 ISPE Annual Meeting Analysis Group Research Posters

POSTER SESSION A

Sunday, August 24 | 8:00 a.m.–6:00 p.m. ET | Convention Hall

Leveraging Real-World Data for Regulatory Commitment: Methodological Considerations in a Post-Approval Safety Study Evaluating the Risk of Atrial Fibrillation (AF) Following Respiratory Syncytial Virus (RSV) Vaccination

Analysis Group Authors

[Mei Sheng Duh](#), Sc.D., M.P.H., *Managing Principal*

[Maral DerSarkissian](#), Ph.D., *Managing Principal*

[Marianne Cunningham](#), Ph.D., *Vice President*

[Catherine Nguyen](#), M.P.H., *Manager*

[Mu Cheng](#), M.P.H., *Manager*

External Coauthors

Pfizer: Joanne Wu, Sc.D., M.S.; Muhammad Younus, M.B.B.S.; Heather Rubino, Ph.D.; and Maria Maddalena Lino, M.D., Ph.D.

White River Junction VA Medical Center: Caroline Korves, Sc.D.; Gabrielle M. Zwain, B.A.; and Abirami Balajee, M.P.H.

Funding for this study was provided by Pfizer.

Real-World Effectiveness of Ravulizumab in Adults With aHUS who Switched to Ravulizumab Within 3 Months of Eculizumab Treatment (aHUS IMPACT)

Analysis Group Authors

[Mei Sheng Duh](#), Sc.D., M.P.H., *Managing Principal*

[Lynn Huynh](#), Ph.D., M.P.H., M.B.A., *Vice President*

Jordan Burdeau, Ph.D., M.S., *Associate*

External Coauthors

Alexion and AstraZeneca Rare Disease: Yan Wang, M.S., Ph.D.; Moh-Lim Ong, M.B.A., M.D., M.P.H.; and Arpita Nag, Ph.D., M.B.A., M.S.

Johns Hopkins University: Shruti Chaturvedi, M.B.B.S., M.S.

The University of California, Irvine: Ramy M. Hanna, M.D.

Funding for this study was provided by Alexion and AstraZeneca Rare Disease.

POSTER SESSION B

Monday, August 25 | 8:00 a.m.–6:00 p.m. ET | Convention Hall

Integrating the Patient Perspective Within Real-World Evidence: A Case Study Linking Routinely Collected Patient-Reported Outcomes and Electronic Health Records from Mass General Brigham Healthcare System

Analysis Group Authors

[Mei Sheng Duh](#), Sc.D., M.P.H., *Managing Principal*

[Maral DerSarkissian](#), Ph.D., *Managing Principal*

[Marianne Cunningham](#), Ph.D., *Vice President*

[Lynn Huynh](#), Ph.D., M.P.H., M.B.A., *Vice President*

[Rose Chang](#), Sc.D., M.S., M.S.P.H., *Vice President*

Louise Clear, M.P.H., *Associate*

Manasvi Sundar, M.P.H., *Associate*

External Coauthors

GSK: Robert Reynolds, Sc.D., M.Sc.; Linda Nelsen, M.H.S.; Tirza Boyle, Ph.D., M.P.H.; and Jonathan Lim, M.Sc., M.Eng., M.S.

Brigham and Women's Hospital: Maria Edelen, Ph.D. and Chengbo Zeng, Ph.D., M.Med.

Harvard Medical School and Mass General Brigham: Yichuan Grace Hsieh, Ph.D., M.S.

Harvard Medical School, Mass General Brigham, and Massachusetts General Hospital: Shawn Murphy, M.D., Ph.D.

Mass General Brigham: Brittany Dragonetti, B.A.; Peter Meyers, B.S.; Greg Belsky, B.S.; and Christopher Herrick, M.B.A.

Funding for this study was provided by GSK.

POSTER SESSION C

Tuesday, August 26 | 8:00 a.m.–1:30 p.m. ET | Convention Hall

Association of Hepatitis B Surface Antigen Loss (HBsAg) with Clinical Outcomes Among Patients with Chronic Hepatitis B Virus (HBV) Infection: A Retrospective Cohort Study in the United States (US)

Analysis Group Authors

[Mei Sheng Duh](#), Sc.D., M.P.H., *Managing Principal*

[Rose Chang](#), Sc.D., M.S., M.S.P.H., *Vice President*

Shuang Wang, Ph.D., M.P.H., *Associate*

Theo Man, M.S., *Senior Analyst*

External Coauthors

GSK: Myriam Drysdale, Ph.D., Pharm.D., M.P.H.; Anna Coutinho, Ph.D., M.S.; and Dickens Theodore, M.D., M.P.H.

Funding for this study was provided by GSK.